AMGN
Amgen Inc.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$438.48
−1.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
18.7x
EV/EBITDA
17.0x
Market Cap
$237.06B
MomentumView details →
1D Return
−1.27%
YTD Return
+35.52%
RSI (14)
68.4
ValuationView details →
P/E (Fwd)
18.7x
EV/EBITDA
17.0x
Market Cap
$237.06B
RSI (14)
68.4
MomentumView details →
1D Return
−1.27%
YTD Return
+35.52%
SummaryUpdated Jun 1, 2026
Amgen Inc. (NASDAQ:AMGN) is one of the world's largest independent biotechnology companies, founded in 1980 and headquartered in Thousand Oaks, California. The company went public in 1983 and has grown to become a leading developer and manufacturer of human therapeutics focused on serious illnesses. Amgen operates globally, serving healthcare providers including physicians, dialysis centers, hospitals, and pharmacies through pharmaceutical wholesale distributors and direct channels. The company has built its reputation on innovative biotechnology medicines, particularly in areas where few treatment options previously existed.
Similar companies
Latest newsMore news →
Amgen announced on Monday that its cholesterol drug Repatha reduced the risk of death by 20% in a study of over 12,000 high-risk patients.4d agoAmgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.8d ago